Merck, Eisai Update Phase 3 LEAP-015 Trial for GE Adenocarcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating...
Category : Clinical Research, Pharma & Healthcare Financing
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...
Corstasis Announces FDA Acceptance for Bumetanide Nasal Spray
PDUFA Target Action Date Set for September 14, 2025 Corstasis Therapeutics Inc. (www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid overload,...
Systech Unveils Semi-Automated Aggregation Solution for Pharma
Systech, part of Markem-Imaje and Dover and a leading provider of digital identification and traceability software solutions, today announced the introduction of the ST16 Semi-Automated Multi-Aggregation Station for pharmaceutical...
Datar Cancer Genetics Launches Tumor-Agnostic MRD Blood Test
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease. Datar...
Breakthrough Study Shows MatriDerm® Superior in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity, Reduce Inflammation, and Deliver Better Wound Healing Outcomes in Research Study MedSkin Solutions...